@文章{信息:doi/10.2196/27202，作者="Ni, Zhao and Wu, Bei and Yang, Qing and Yan, Lijing L and Liu, Changqing and Shaw, Ryan J"，标题="mHealth干预改善冠心病患者药物依从性和健康预后:随机对照试验"，期刊="J Med Internet Res"，年="2022"，月="3"，日="9"，卷="24"，数="3"，页数="e27202"，关键词="mHealth;药物治疗的依从性;冠状动脉疾病;血压;中国;背景:许多慢性疾病的治疗涉及长期药物治疗，但找到有效的方法来提高药物依从性以促进良好的健康结果是一个持续的挑战。心脏保护药物可预防冠心病患者有害凝块扩大、心血管症状和治疗效果差，如高血压和高脂血症无法控制。然而，心血管保护药物依从性差已被报道为冠心病患者的一个全球性健康问题，在中国尤其令人担忧。目的:本研究旨在评估移动健康(mHealth)干预的效果，使用2个移动应用程序来改善药物依从性和健康结果。方法:在位于中国成都的一所主要大学附属医疗中心进行了一项随机、安慰剂对照、两组平行研究。 Participants were recruited by flyers and health care provider referrals. Each participant was observed for 90 days, including a 60-day period of mHealth intervention and a 30-day period of nonintervention follow-up. The study coordinator used WeChat and Message Express to send educational materials and reminders to take medication, respectively. Participants used WeChat to receive both the educational materials and reminders. Participants in the control group only received educational materials. This study received ethics approval from the Duke Health Institutional Review Board (Pro00073395) on May 5, 2018, and was approved by West China Hospital (20170331180037). Recruitment began on May 20, 2018. The pilot phase of this study was registered on June 8, 2016, and the current, larger-scale study was retrospectively registered on January 11, 2021 (ClinicalTrials.gov). Results: We recruited 230 patients with coronary heart disease. Of these patients, 196 completed the baseline survey and received the intervention. The majority of participants were married (181/196, 92.4{\%}), male (157/196, 80.1{\%}), and lived in urban China (161/196, 82.1{\%}). Participants' average age was 61 years, and half were retired (103/191, 53.9{\%}). More than half the participants (121/196, 61.7{\%}) were prescribed at least 5 medications. The mean decrease in medication nonadherence score was statistically significant at both 60 days (t179=2.04, P=.04) and 90 days (t155=3.48, P<.001). Systolic blood pressure and diastolic blood pressure decreased in the experimental group but increased in the control group. The mean decrease in diastolic blood pressure was statistically significant at both 60 days (t160=2.07, P=.04) and 90 days (t164=2.21, P=.03). The mean decrease in systolic blood pressure was significantly different in the groups at 90 days (t165=3.12, P=.002). Conclusions: The proposed mHealth intervention can improve medication adherence and health outcomes, including systolic blood pressure and diastolic blood pressure. Trial Registration: ClinicalTrials.gov NCT02793830; https://clinicaltrials.gov/ct2/show/NCT02793830 and ClinicalTrials.gov NCT04703439; https://clinicaltrials.gov/ct2/show/NCT04703439 ", issn="1438-8871", doi="10.2196/27202", url="//www.mybigtv.com/2022/3/e27202", url="https://doi.org/10.2196/27202", url="http://www.ncbi.nlm.nih.gov/pubmed/35262490" }